AbCellera Biologics (ABCL) News Today → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free ABCL Stock Alerts $3.64 -0.14 (-3.70%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 8:42 AM | markets.businessinsider.comKeyBanc Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)May 16 at 8:39 AM | seekingalpha.comAbCellera: If You Build It, Will They Come? Fresh Impetus RequiredMay 15, 2024 | seekingalpha.comAbCellera: Cash Providing Shelter From Market WeaknessMay 13, 2024 | investorplace.com3 Stock Gems Hiding in the NasdaqMay 13, 2024 | americanbankingnews.comAbCellera Biologics Inc. to Post Q2 2024 Earnings of ($0.15) Per Share, Bloom Burton Forecasts (NASDAQ:ABCL)May 12, 2024 | americanbankingnews.comAbCellera Biologics Inc. (NASDAQ:ABCL) to Post FY2026 Earnings of ($0.67) Per Share, Bloom Burton ForecastsMay 11, 2024 | americanbankingnews.comLeerink Partnrs Research Analysts Lower Earnings Estimates for AbCellera Biologics Inc. (NASDAQ:ABCL)May 10, 2024 | marketbeat.comBloom Burton Comments on AbCellera Biologics Inc.'s FY2026 Earnings (NASDAQ:ABCL)AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) - Bloom Burton issued their FY2026 EPS estimates for AbCellera Biologics in a research note issued on Thursday, May 9th. Bloom Burton analyst D. Martin forecasts that the company will post earnings per share of ($0.67) for the year. The consensMay 10, 2024 | finance.yahoo.comEarnings Release: Here's Why Analysts Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$12.71May 10, 2024 | americanbankingnews.comKeyCorp Lowers AbCellera Biologics (NASDAQ:ABCL) Price Target to $7.00May 8, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: ICU Medical (ICUI), AbCellera Biologics (ABCL)May 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for AbCellera Biologics on Strong Financials and Promising PartnershipsMay 8, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) PT Lowered to $7.00 at KeyCorpKeyCorp lowered their target price on AbCellera Biologics from $8.00 to $7.00 and set an "overweight" rating on the stock in a research note on Wednesday.May 8, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPSAbCellera Biologics (NASDAQ:ABCL - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.02. AbCellera Biologics had a negative return on equity of 12.36% and a negative net margin of 384.99%. The firm had revenue of $9.95 million during the quarter, compared to analyst estimates of $10.73 million. During the same quarter in the prior year, the company earned ($0.14) EPS. The business's revenue was down 18.4% compared to the same quarter last year.May 8, 2024 | fool.comAbCellera Biologics (ABCL) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comQ1 2024 Abcellera Biologics Inc Earnings CallMay 7, 2024 | investorplace.comABCL Stock Earnings: AbCellera Biologics Beats EPS, Misses Revenue for Q1 2024May 7, 2024 | finance.yahoo.comAbCellera Biologics Inc (ABCL) Q1 2024 Earnings: Misses Revenue and Net Loss EstimatesMay 7, 2024 | businesswire.comAbCellera Reports Q1 2024 Business ResultsMay 6, 2024 | markets.businessinsider.comWhat Wall Street expects from AbCellera Biologics's earningsMay 3, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Trading Up 7%AbCellera Biologics (NASDAQ:ABCL) Trading Up 7%May 2, 2024 | finance.yahoo.comInsider Stock Buying Reaches US$1.61m On AbCellera BiologicsMay 1, 2024 | businesswire.comAbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech CompaniesApril 25, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Sets New 52-Week Low at $3.76AbCellera Biologics (NASDAQ:ABCL) Sets New 1-Year Low at $3.76April 24, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Trading 4.3% Higher AbCellera Biologics (NASDAQ:ABCL) Shares Up 4.3%April 18, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Hits New 12-Month Low at $3.84AbCellera Biologics (NASDAQ:ABCL) Hits New 52-Week Low at $3.84April 18, 2024 | finance.yahoo.comAbCellera Biologics Inc. (ABCL)April 10, 2024 | marketbeat.comAbCellera Biologics Inc. (NASDAQ:ABCL) Shares Sold by Baillie Gifford & Co.Baillie Gifford & Co. trimmed its holdings in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 8.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 24,044,796 shares of the company's stock after selling 2,159,853 shares during thApril 9, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Shares Up 5.1%AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 5.1%April 8, 2024 | businesswire.comAbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024April 6, 2024 | marketbeat.comAbCellera Biologics Inc. (NASDAQ:ABCL) Receives Average Rating of "Buy" from AnalystsAbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) has been assigned an average rating of "Buy" from the seven research firms that are covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 1 year price objective among analystsApril 3, 2024 | businesswire.comAbCellera to Report First Quarter 2024 Financial Results on May 7, 2024April 1, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Trading Down 3.8%AbCellera Biologics (NASDAQ:ABCL) Trading Down 3.8%March 27, 2024 | investorplace.comThe 7 Best Penny Stocks to Buy in Q2 2024March 27, 2024 | finance.yahoo.comBillionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 11 StocksMarch 26, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Stock Price Down 3.7%AbCellera Biologics (NASDAQ:ABCL) Shares Down 3.7%March 19, 2024 | businesswire.comAbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024March 11, 2024 | msn.comAbCellera gains on antibody collaboration with BiogenMarch 11, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Stock Price Up 4.8%AbCellera Biologics (NASDAQ:ABCL) Trading 4.8% HigherMarch 9, 2024 | marketbeat.comSchonfeld Strategic Advisors LLC Acquires 211,000 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL)Schonfeld Strategic Advisors LLC boosted its position in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 143.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 358,400 shares of the cMarch 5, 2024 | businesswire.comAbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024March 5, 2024 | marketbeat.comTrexquant Investment LP Has $1.25 Million Position in AbCellera Biologics Inc. (NASDAQ:ABCL)Trexquant Investment LP lifted its position in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 458.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 272,158 shares of the company's stock after buyiMarch 3, 2024 | marketbeat.comBarclays PLC Sells 504,978 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL)Barclays PLC decreased its holdings in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 96.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,986 shares of the company's stock after selling 504,978 sFebruary 29, 2024 | finance.yahoo.comAfter losing 38% in the past year, AbCellera Biologics Inc. (NASDAQ:ABCL) institutional owners must be relieved by the recent gainFebruary 28, 2024 | seekingalpha.comAbCellera: Victim Of Its Own SuccessFebruary 26, 2024 | marketbeat.comFederated Hermes Inc. Cuts Position in AbCellera Biologics Inc. (NASDAQ:ABCL)Federated Hermes Inc. reduced its stake in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 3.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,254,353 shares of the company's stock after selling 119,702 shares duringFebruary 26, 2024 | investorplace.com3 Highly Rated Biotech Stocks to Buy for 300% GainsFebruary 23, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)February 23, 2024 | businesswire.comAbCellera Announces Resignation of Board MemberFebruary 23, 2024 | finance.yahoo.comABCL Mar 2024 4.000 call Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address Exposed: 10 CENT Crypto to Explode May 20th? (Ad)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career… Click For My #1 FREE Crypto for 2024 ABCL Media Mentions By Week ABCL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABCL News Sentiment▼0.110.42▲Average Medical News Sentiment ABCL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABCL Articles This Week▼83▲ABCL Articles Average Week Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Verona Pharma News Today MannKind News Today Enliven Therapeutics News Today Collegium Pharmaceutical News Today Mirum Pharmaceuticals News Today Pacira BioSciences News Today Spyre Therapeutics News Today Belite Bio News Today Prothena News Today Gyre Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABCL) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 Media41 banks launch ‘crypto dollar’Stansberry ResearchExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
